RYTM Rhythm Pharmaceuticals Inc.

14.87
-0.35  -2%
Previous Close 15.22
Open 14.99
Price To Book 2.33
Market Cap 655,155,977
Shares 44,058,909
Volume 493,169
Short Ratio
Av. Daily Volume 255,819
Stock charts supplied by TradingView

NewsSee all news

  1. Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations

     Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA   Precautionary measures in place to mitigate impact of COVID-19 on clinical programs 

  2. Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities

    BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic

  3. Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome

    BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic

  4. Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    -- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 -- -- Granted orphan drug designation by the European Medicines Agency for

  5. Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

    BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data updates expected in 2020.
Setmelanotide (basket)
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 3 top-line data due 4Q 2020 or early 1Q 2021.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome
NDA filing announced March 30, 2020.
Setmelanotide
Leptin Receptor Deficiency Obesity
NDA filing due announced March 30, 2020.
Setmelanotide
POMC deficiency obesity

Latest News

  1. Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations

     Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA   Precautionary measures in place to mitigate impact of COVID-19 on clinical programs 

  2. Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities

    BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic

  3. Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome

    BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic

  4. Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    -- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 -- -- Granted orphan drug designation by the European Medicines Agency for

  5. Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

    BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders

  6. Rhythm Pharmaceuticals Announces Leadership Transition

    Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020 Board Forms Search Committee to

  7. Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

    -- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) --  Rhythm

  8. Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

  9. Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

    -- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index --  -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral

  10. Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and

  11. Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

  12. Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

    BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic

  13. Rhythm Pharmaceuticals Provides Update on Research and Development Programs

    -- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individuals) who have a

  14. Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

    -- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for

  15. Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of